Clinical trials: Renin Hypertension
Hypertension
A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)
This study will evaluate the safety and efficacy of long term treatment of SPP100 in patients with essential hypertension. (Trial is not recruiting in the US)
- Trial name
- NCT00246584
- Testing
- SPP100
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- Novartis
Uncontrolled Hypertension
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension
This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in uncontrolled hypertension.
- Trial name
- NCT07654140
- Testing
- SAL0140
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypertension,Essential
Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients
SPH3127 tablet is a of renin inhibitor. It is expected to be a new drug for essential hypertension. This is a phase IIa trial which designed to evaluate its efficacy and safety on treating mild-moderate essential hypertension…
- Trial name
- NCT03756103
- Testing
- SPH3127 tablet Dose 1, SPH3127 tablet Dose 2, SPH3127 tablet Dose 3
- Where
- 10 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Hypertension
Effect of Light Meal on Pharmacokinetic and Pharmacodynamics of Aliskiren in Patients With Mild to Moderate Hypertension
The purpose of this study is to determine the effect of a light meal on the pharmacokinetics and pharmacodynamics of aliskiren in patients with mild to moderate hypertension.
- Trial name
- NCT00933920
- Testing
- Aliskiren
- Where
- 5 sites in India
- Volunteers
- 124 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension
This study is conducted to investigate the effect of the oral renin inhibitor SPP635 on blood pressure in patients with mild to moderate hypertension.
- Trial name
- NCT00376636
- Testing
- SPP635 (drug)
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Speedel Pharma Ltd.
Hyperkalemia
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
- Trial name
- DIAMOND (NCT03888066)
- Testing
- Patiromer
- Where
- 415 sites in United States, Argentina and 19 more
- Volunteers
- 1,195 people
- Sponsor
- Vifor Pharma, Inc.
Hypertension
Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients
This study is designed as a mechanistic study to compare the effect of two different combinations of anti-hypertensive treatments (aliskiren and valsartan vs.
- Trial name
- NCT00939588
- Testing
- Aliskiren/ Valsartan, Telmisartan/ Ramipril
- Where
- Russia
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension
Assessing efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension
- Trial name
- NCT00344110
- Testing
- Aliskiren
- Where
- Japan
- Volunteers
- 768 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.
- Trial name
- NCT00765674
- Testing
- Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ)
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 1,191 people
- Sponsor
- Novartis
Hypertension, Abdominal Obesity
Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension
Part 1 determined: aliskiren, amlodipine and angiotensin II concentrations in interstitial fluid of fat and skeletal muscle; aliskiren and angiotensin II concentrations, and renin activity and concentration in fat and skeletal…
- Trial name
- NCT00498433
- Testing
- Aliskiren, Amlodipine
- Where
- 2 sites in Germany
- Volunteers
- 46 people
- Sponsor
- Novartis
Hypertension
A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age
This first open-label study in a pediatric population was designed to evaluate aliskiren safety and pharmacokinetics after single and multiple dosing in 6-17 year old children with hypertension.
- Trial name
- NCT00834041
- Testing
- Aliskiren 3.125 mini-tablets
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Novartis
Hypertension
Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet
This study will measure the effects of different doses of aliskiren on kidney blood flow and function in healthy adults and determine how salt intake affects the response to aliskiren.
- Trial name
- NCT00518765
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novartis
Arterial Hypertension
Survey to Assess Why People Are Not Responding to Treatment in Hypertension
This study will describe the factors influencing the physician in face of elevated blood pressure in already treated patients
- Trial name
- NCT01071681
- Testing
- Telmisartan (Kinzal/Pritor, BAY68-9291)
- Where
- France
- Volunteers
- 1,589 people
- Sponsor
- Bayer
Hypertension With Metabolic Syndrome
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
This proof of concept study is designed to evaluate the efficacy and safety of the combination therapy of aliskiren and ramipril as add-on to amlodipine in the treatment of patients with essential hypertension and metabolic…
- Trial name
- ALTO (NCT00542269)
- Testing
- Amlodipine, Aliskiren, Ramipril
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- Novartis
Hypertension, Type II Diabetes Mellitus
Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria
This is a phase II a, double-blind, randomized, parallel-design, four-week study to investigate the efficacy, safety and tolerability of two different doses of SPP635 in type II diabetic patients with mild to moderate…
- Trial name
- NCT00561171
- Testing
- SPP635
- Where
- Ireland
- Volunteers
- 50 people
- Sponsor
- Speedel Pharma Ltd.